New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
13:25 EDTACAD, ACAD, CYTK, CYTK, GILD, GILD, SHPG, SHPG, SNY, SNY, ACOR, ACOR, ALXN, ALXN, FURX, FURX, THLD, THLDCowen to host a conference
33rd Annual Health Care Conference is being held in Boston on March 4-6 with webcasted company presentations to begin on March 4 at 1:30 pm; not all company presentations may be webcasted. Webcast Link
News For ACAD;CYTK;GILD;SHPG;SNY;ACOR;ALXN;FURX;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 18, 2015
14:42 EDTGILDAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
16:01 EDTGILDOptions Update; May 15, 2015
iPath S&P 500 VIX Short-Term Futures down 20c to 20.06 Option volume leaders: AAPL BAC FB NFLX TWTR BABA CSCO TSLA MU GILD T MSFT AMZN MCD
11:08 EDTSHPG, GILDOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTGILDAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
07:47 EDTALXNAlexion risk/reward profile favorable, says Barclays
Subscribe for More Information
May 13, 2015
17:38 EDTTHLDThreshold Pharmaceuticals to present clinical update on evofosfamide at ASCO
Subscribe for More Information
13:12 EDTGILDSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
07:31 EDTGILD, SNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
May 12, 2015
09:20 EDTTHLDOn The Fly: Pre-market Movers
Subscribe for More Information
07:52 EDTSHPG, ACORLeerink to hold a tour
Subscribe for More Information
06:09 EDTTHLDThreshold announces Merck receives FDA Fast Track designation for evofosfamide
Subscribe for More Information
May 8, 2015
14:54 EDTALXNAlexion management to meet with JPMorgan
Subscribe for More Information
14:53 EDTALXNAlexion management to meet with JPMorgan
Subscribe for More Information
13:25 EDTCYTKCytokinetics to host research and development day with a conference call hookup
Research and Development meeting to be held in New York on May 12 at 8 am. Webcast Link
08:47 EDTSHPGLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discuss the future of dry eye treatment and the data and outlook for pipeline agents Shire's Lifitegrast and Eleven Biotherapeutics' EBI-005 and expectations for Actavis' Restasis use, assuming future approval of one or more pipeline agents, on an Analyst/Industry conference call to be held on May 12 at 10:30 am.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use